Menu ×

HEALTHCARE & PHARMACEUTICAL

Chikungunya Treatment Market Segmentation by Strain Type (Aedes Aegypti, and Aedes Albopictus); by Drug Class (Analgesics, Antipyretics, Vaccines, and Others); by Route of Administration (Oral and Parenteral); and by End User (Hospitals and Clinics, Academic Institutes, Research Laboratories, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Chikungunya Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • February 2019- Moderna, Inc. initiated the first dose in patients in phase I clinical trial for mRNA-1944, which is an anti-chikungunya antibody for the treatment of chikungunya viral infections.

  • February 2019- Themis Bioscience received the fast-track designation for MV-CHIK, a vaccine for treating chikungunya viral infections from the United States food and drug administration, FDA.

Global Chikungunya Treatment Market Highlights 2022 – 2030

The global chikungunya treatment market is estimated to garner a hefty amount of revenue and grow at a CAGR of ~7% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing occurrence of chikungunya, and rise in awareness about mosquito-transmitted infections around the world. According to the World Health Organization, Asia and the Americas were the regions most affected by chikungunya. Pakistan faced a persistent outbreak that started in the year 2017 and reported 8,387 cases, while India suffered with 62,000 cases. Apart from these, ongoing government initiatives regarding prevention control of mosquito breeding, coupled with rising consciousness among people associated with mosquito bites and its consequences, are also expected to be crucial factors driving market growth in the upcoming years. Furthermore, escalating unmet needs for chikungunya diagnosis in the developing and under-developed regions of Asia and Africa, are projected to further the scope of medical examination possibilities for disease control, which in turn is assessed to offer profitable opportunities to the market in the near future.   

Chikungunya Treatment Market Graph

The market is segmented by end user into hospitals and clinics, academic institutes, research laboratories, and others, out of which, the hospitals and clinics segment is anticipated to hold the largest share in the global chikungunya treatment market. This can be accounted to the large patient pool of chikungunya in hospitals, and high preference of people to be treated in a well-established healthcare facility. In addition, the research laboratories segment is predicted to observe the highest CAGR over the forecast period owing to the increasing number of ongoing researches to develop specific treatment for curing the chikungunya virus. Moreover, on the basis of route of administration, the oral segment is evaluated to occupy the largest share over the forecast period, which can be credited to the cost-effectiveness, non-invasive nature and convenience of taking drugs by this route of dosage.  CLICK TO DOWNLOAD SAMPLE REPORT    

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Exoenditure Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Chikungunya Treatment Market Regional Synopsis

On the basis of geographical analysis, the global chikungunya treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the growing prevalence of mosquito-transmitted diseases, and rising number of alliances among western market players. Along with these, subsistence of unsanitary conditions in several regions of the Asia is also anticipated to drive APAC’s market growth in the coming years. Additionally, the market in North America is expected to acquire the most significant share during the forecast period ascribing to the extensive research and development activities in the healthcare sector, especially in the United States, and presence of well-established healthcare infrastructure in the region. As per the data provided by the Centers for Medicare and Medicaid Services, U.S. health care spending reached USD 3.8 trillion in 2019. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent.

Chikungunya Treatment Market Share Graph

The global chikungunya treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global chikungunya treatment market includes the following segments:

By Strain Type

  • Aedes Aegypti
  • Aedes Albopictus

By Drug Class

  • Analgesics
  • Antipyretics
  • Vaccines
  • Others

By Route of Administration

  • Oral
  • Parenteral

By End User

  • Hospitals and Clinics
  • Academic Institutes
  • Research Laboratories
  • Others

Growth Drivers

  • Growing Occurrence of Chikungunya Globally
  • Rising Awareness About Mosquito-Transmitted Infections

Challenges

  • Lack of Skilled Professionals for Treating Chikungunya Fever

Top Featured Companies Dominating the Market

  • Bio-Rad Laboratories, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Quest Diagnostics Incorporated.
  • Sanat Products Ltd.
  • Taj Pharmaceuticals Limited.
  • Etubics Corporation
  • Genome Diagnostics Pvt. Ltd.
  • Altona Diagnostics
  • Paradigm Biopharmaceuticals Ltd
  • Themis Bioscience GmbH
  • Moderna Inc.

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved